Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of PH for each country, as well as annualized case counts projected to the national population.
Most patient populations in the mature pharmaceutical markets are forecast over a period of 20 years; in other countries, forecasts cover 10 years. In addition to forecasting prevalent patient populations, we calculate the number of drug-treatment opportunities in specific lines of therapy in the mature pharmaceutical markets.
Clarivate Epidemiology’s PH forecast will answer the following questions:
How will changes in the levels of exposure to known risk or protective factors affect the number of people living with PH?
Of all people with PH, how many in each country have been formally diagnosed?
Of all people diagnosed with PH, how many in the mature pharmaceutical markets are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of PH over the forecast period?
All forecast data are available on the Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph of the patient flow between or within different disease states for the mature pharmaceutical markets. These patient flows are provided at the regional level but may be requested for any specific country or forecast year.
Clarivate Epidemiology provides at least 10 years of forecast data for the following PH patient populations:
Ullas Ulahannan, MPH., Epidemiologist, Epidemiology. Before joining Clarivate, he worked at Jhpiego (a John Hopkins University affiliate) as a senior program officer evaluating, implementing, and monitoring various health programs in collaboration with the state and central governments of India. His qualifications include a master’s degree in public health from Manipal University, Manipal, and a bachelor’s degree in nursing from Rajiv Gandhi University of Health Sciences, Bangalore
Swarali Tadwalkar
Swarali Tadwalkar, M.P.H., is a principal epidemiologist at Clarivate. Previously, she was involved in primary and secondary healthcare research, including projects in digital health, health policy and management, and health economics and outcomes research (HEOR). Ms. Tadwalkar also coordinated various nongovernmental public health projects focusing on access to treatment for hepatitis and human papilloma virus. She received her M.P.H. from the University of South Florida in Tampa.
